2929 N Commerce Parkway
Miramar, FL 33025
July 16, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Abby Adams |
Laura Crotty
| Re: | HCW Biologics Inc. |
Registration Statement on Form S-1
File No. 333-256510
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Acceleration Request
| Requested Date: | July 19, 2021 | |||
| Requested Time: | 4:00 p.m. Eastern Time |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, HCW Biologics Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the Company’s Registration Statement on Form S-1 (File No. 333-256510) effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Company hereby authorizes William L. Hughes, who is an attorney with the Company’s outside legal counsel, Orrick, Herrington & Sutcliffe LLP, to orally modify or withdraw this request for acceleration.
The Company requests that it be notified of such effectiveness by a telephone call to Mr. Hughes at (415) 773-5720.
[Signature page follows]
| Sincerely, | ||
| HCW BIOLOGICS INC. | ||
| By: | /s/ Rebecca Byam | |
| Name: Rebecca Byam Title: Chief Financial Officer | ||
| cc: | William L. Hughes, Esq, Orrick, Herrington & Sutcliffe LLP |
Scott M. Iyama, Esq., Orrick, Herrington & Sutcliffe LLP
Hing C. Wong, HCW Biologics Inc.
Rebecca Byam, HCW Biologics Inc.